Photobiomodulation Therapy for Idiopathic Facial Paralysis
Bell's Palsy
About this trial
This is an interventional treatment trial for Bell's Palsy focused on measuring Idiopathic facial paralysis, Bell's palsy, photobiomodulation, RCT
Eligibility Criteria
Inclusion Criteria:
- (1) Adults over 18 years of age and under 60 years of age. (2) The patients were informed and signed the informed consent.
Exclusion Criteria:
- (1) Planning for pregnancy, in pregnancy or lactation. (2) Greater than 90% denervation on ENoG. (3) No voluntary EMG activity. (4) Systemic disease, such as severe diabetes, malignant tumors and other serious consumptive diseases.
(5) Serious mental illness or social problems, and neurological disorders. (6) Planning for pregnancy, in pregnancy or lactation.
Sites / Locations
- Beijing TongRen Hospital, Capital Medical University
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
PBMT Group
Control Group
Treatments were performed with MLS laser (Mphi laser, ASA Srl, Italy). MLS laser is a class IV NIR laser with two synchronized sources (laser diodes). The first one is a pulsed laser diode, emitting at 905 nm, with 25 W peak power. The second laser diode (808 nm) was operated in a continuous mode with power 1 W. Both of the laser beams were synchronized, the locked waves work within the range 1-2000 Hz.
Control group were received prednisolone acetate treatment, took prednisolone acetate 24 mg once a day for 1 week.